Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | UMPS | P11172 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466334 | 1.00 | PNP (0.47) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL4588335 | 1.00 | PNP (0.47) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL2778662 | 1.00 | PNP (0.47) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL5574710 | 1.00 | PNP (0.47) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL29122970 | 0.99 | PNP (0.46) | PNPHIF1APYGL | |
| SCHEMBL17873225 | 0.82 | PNP (0.44) | PNPHIF1ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14365990 | 0.81 | PNP (0.50) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL10081193 | 0.81 | PNP (0.50) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL14066117 | 0.81 | PNP (0.50) | PNPHIF1ALMNASMN1; SMN2MTOR | |
| SCHEMBL902517 | 0.81 | PNP (0.50) | PNPHIF1ALMNASMN1; SMN2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015723-A1 | Antiviral oligonucleotides having a conserved G4 core sequence | ISIS PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| EP-0672193-B1 | USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT | ISIS PHARMACEUTICALS INC (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6310044-B1 | ANTISENSE PHOSPHORTHIOATE OR METHYLPHOSPHONATE OLIGONUCLEOTIDES OF GIVEN SEQUENCE, COMPLEMENTARY TO A TRANSLATION INITIATION PORTION OF MRNA FROM A HERPES VIRUS OPEN READING FRAME | ISIS PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| EP-1016715-A1 | Oligonucleotides having a conserved G4 core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5952490-A | A CHEMICALLY MODIFIED OLIGONUCLEOTIDE THAT INHIBITS VIRAL ACTIVITY OR PHOSPHOLIPASE A; TREATMENT OF AGING AND MALIGNANT CELL GROWTH | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0517859-B1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS INC (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5658891-A | CONTACTING CELLS OF EYE WITH ANTIBODY | ISIS PHARMACEUTICALS, INC. | 1997-08-19 | — | — | US | disclosed |
| US-5514577-A | TREATMENT OF HERPES VIRUS WITH OLIGONUCLEOTIDES AS VIRICIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0692930-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0672193-A1 | OLIGONUCLEOTIDES HAVING A CONSERVED G 4? CORE SEQUENCE | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994019945-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994008053-A1 | OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5248670-A | Phosphorothioate internucleotide bonds | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| EP-0517859-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991012811-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1991-09-05 | — | — | WO | disclosed |